Novilla is developing a patented drug delivery system that provides an alternative to opioids for pain management. This technology aims to mitigate the public health crisis posed by the opioid epidemic by offering a safer therapeutic option.
Funding
$9M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
The opioid epidemic poses a significant public health crisis, creating a need for safer and non-addictive pain management alternatives. Traditional drug delivery methods often expose the entire body to therapeutics, leading to unwanted side effects and potential addiction risks.
Solution
Novilla Pharmaceuticals is developing a patented drug delivery platform designed to bypass the bloodstream, delivering therapeutics directly to the site of action. This targeted approach aims to maximize efficacy while minimizing systemic exposure, thereby reducing side effects and the risk of addiction. The platform seeks to provide an alternative to opioids for pain management by enhancing the penetration of existing therapies into the dermal layer. By avoiding systemic circulation, Novilla's technology intends to create fundamentally better therapeutics with full efficacy and a reduced risk profile.
Target Audience
The primary target audience includes patients seeking non-opioid pain management options and pharmaceutical companies looking to improve the safety and efficacy of their existing pain therapeutics.
Features
- Patented drug delivery system for targeted therapeutic administration.
- Bypasses the bloodstream to minimize systemic exposure.
- Enhances dermal penetration of existing therapies.
- Designed to reduce side effects and addiction risks associated with traditional pain management.